妇科恶性肿瘤（GMs）是肿瘤学家和研究人员相对较少关注的癌症。在过去十年中，GMs患者的五年生存率几乎保持不变。GMs耐药性的发展使其更加具有挑战性，原因是肿瘤异质性、基因组不稳定性、病毒/非病毒抗原和病因性肿瘤起源。正在测试精准医学方法，包括基因治疗，以恢复肿瘤对治疗和免疫疗法的反应性。随着越来越多的数据被揭示，免疫疗法正在成为取得有希望结果的可行选择。本综述突出了药物耐药机制和免疫治疗方法对于更好地管理GMs的重要性。近年来免疫治疗药物的批准改变了这一观念，给GMs研究人员、临床医生和患者带来了希望，使他们能够体验到这些疗法的抗癌益处。版权所有©2023。Elsevier Inc.发表。

Gynecologic malignancies (GMs) are relatively less focused cancers by oncologists and researchers. The five-year survival rate of patients with GMs remained almost the same during the last decade. The development of drug resistance GMs makes it even more challenging to tackle due to tumor heterogeneity, genomic instability, viral/non-viral antigens, and etiological tumor origin. A precision medicine approach, including gene therapies, is under testing to restore tumor responsiveness to therapeutics and immunotherapy. With more data being uncovered, immunotherapy is emerging as a viable alternative for achieving promising results. This review highlights the drug resistance mechanisms and immunotherapeutic approaches to managing GMs better. The approval of immune therapeutic drugs in recent years shifted this notion. It provided hope for researchers, clinicians, and patients with GMs to experience the anti-cancer benefits of these therapies.Copyright © 2023. Published by Elsevier Inc.